This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Health technology
A timely consult with a multidisciplinary antimicrobial therapy team composed of pharmacists, a clinical microbiologist, and an infectious disease specialist, for hospitalised patients receiving intravenous antimicrobials. A number of methods were used to identify eligible patients: daily screening of culture and susceptibility reports and review of antibiotic orders, chart reviews of patients in the intensive care unit (ICU), review of aminoglycoside and vancomycin levels, drug profiles for all patients with serum creatinine levels above 1.8 mg/dl, and chart reviews of all patients receiving imipenem-cilastatin. Physicians received timely, detailed reviews of relevant microbiologic and clinical data with recommendations for possible optimal antibiotic choices, dosages, and rationales.
Type of intervention
Treatment.
Economic study type
Cost-effectiveness analysis.
Study population
The study population was patients with documented or suspected infectious diseases who could benefit from the intervention. First-and second-phase eligibility criteria were applied. In the first 6 months of the study, the patients whose culture and susceptibility reports indicated significant bacterial resistance in vitro were included in the study. After this period, patients with the following characteristics were also included: inappropriate empiric therapy (antibiotic therapy not believed to cover anticipated organisms); incorrect dosing on the basis of renal function; redundant antibiotics; significant drug interactions, antibiotics that could cause substantial comorbidities with associated disease states (e.g. ascites, congestive heart failure, altered mental status, and malabsorption, and age over 80 years); an expensive regimen; and excessive duration of intravenous antibiotics. The following patients were excluded: those with dangerously inappropriate regimens who ethically could not be randomised to the control arm, those for whom a consultation from one of the coinvestigators had been requested, and those whose charts documented expected death or discharge within 48 hours of the review.
Setting
Hospital. The economic study was carried out in the USA.
Dates to which data relate
Effectiveness and resource use data corresponded to patients enrolled between 1 September 1994 and 10 March 1996. The price year was 1999.
Link between effectiveness and cost data
Costing was prospectively undertaken on the same patient sample as that used in the effectiveness analysis.
Study sample
Power calculations were not used to determine the sample size. Out of 272 patients initially randomised, the final study sample consisted of 252 consecutive patients receiving suboptimal intravenous antibiotics identified by the clinical pharmacist. 127 were randomly assigned to the intervention group (mean (SD) age of 66 (19) years) and 125 to the control group (mean (SD) age of 69 (17) years). 20 randomised patients (9 control and 11 intervention) were excluded as they were considered not to be eligible for the analysis.
Study design
This was a randomised controlled study, carried out in a single centre. The duration of the follow-up was until discharge or in-hospital death. Loss to follow-up was not reported except for the 20 randomised patients (9 control, 11 intervention) who were excluded from the analysis. Eligible patients were blindly randomised to the intervention or control group. Patients were stratified by infectious disease category (IDC). Within IDC strata, randomisation was carried out in blocks of four (two to each study arm).
Analysis of effectiveness
The principle used in the analysis of effectiveness appears to have been treatment completers only. The primary end point of the study was length of stay after randomisation (LOS2). Other health outcomes were survival, types of intervention (simple versus complex consults, and empiric versus culture-specific therapy), and physician acceptance. The study groups were comparable in terms of severity of illness indicators, infection type, and time from admission to randomisation. Weibull regression was used to compare intervention and control group medians while controlling for baseline variables characterising severity of illness (age, ventilator dependency, mental status, infectious disease category, ambulatory status). Time-specific mortality rates were compared between arms, and differences were compared between various strata using Cox proportional hazards regression.
Effectiveness results
The median length of stay after randomisation for the control group was 9 days and for the intervention group was 5.7 days, (3.3 day difference, p=0.0001). Intervention LOS2 remained significantly lower overall after adjusting for the complexity of interventions, and was significantly lower for both complex (p=0.018) and simple interventions (p=0.001). After adjusting for the empiric status of interventions, intervention LOS2 remained significantly lower overall and also in both empiric and culture-driven consults, (p=0.008). Fifteen (12%) and eight patients (6.3%), respectively, died, although the time specific mortality risk was not significantly different when length of postrandomisation follow-up and time to death were taken into account. Complex and simple interventions or empiric status of the consults did not affect the difference in mortality rates between the groups. Physician acceptance of suggestions was 89%.
Clinical conclusions
It is unlikely that factors other than the interventions were responsible for the improved outcomes, because the study was randomised and the severity-of-illness measures of the two groups were similar. The large therapeutic benefit observed was the result of patient selection, physician compliance, and the comprehensive, multidisciplinary nature of consults.
Measure of benefits used in the economic analysis
No summary benefit measure was identified in the economic analysis, and only separate clinical outcomes were reported separately.
